Company news
Sunshine Biopharma Inc. (NASDAQ:SBFM) news
Every Sunshine Biopharma Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
August 31, 2026
Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer
August 26, 2026
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
August 19, 2026
Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market
August 7, 2026
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval
August 4, 2026
Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting
July 28, 2026
Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
July 20, 2026
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)
June 25, 2026
Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
June 1, 2026
Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology
May 29, 2026
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
May 28, 2026
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin
May 21, 2026
Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering
May 19, 2026
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
May 18, 2026
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
April 6, 2026
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
October 28, 2025
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea
October 28, 2025
Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline
October 20, 2025
Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin
October 16, 2025
Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience
October 14, 2025
Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections
October 9, 2025
Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market
July 2, 2025
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market
June 11, 2025
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year
May 15, 2025
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market
May 6, 2025
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion
April 21, 2025
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering
April 3, 2025
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
April 2, 2025
Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer
April 2, 2025
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
April 1, 2025
SUNSHINE BIOPHARMA EXPANDS PRESENCE IN THE $53.9 BILLION GLOBAL ANTIBIOTICS MARKET WITH THE ACQUISITION OF MARKETING RIGHTS FOR TWO NEW A...
March 25, 2025
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New A...
March 24, 2025
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
March 10, 2025
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
January 21, 2025
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
January 15, 2025
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus
December 9, 2024
Sunshine Biopharma Launches a New Generic Prescription Drug
December 4, 2024
Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepa...
December 2, 2024
Sunshine Biopharma Launches a New Generic Prescription Drug
November 22, 2024
Sunshine Biopharma : Business/Financial Results Form 8 K
November 7, 2024
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%
November 6, 2024
SUNSHINE BIOPHARMA LAUNCHES TWO NEW GENERIC PRESCRIPTION DRUGS
September 27, 2024
Sunshine Biopharma Launches Two New Generic Prescription Drugs
September 26, 2024
Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry
September 4, 2024
SUNSHINE BIOPHARMA HAS LAUNCHED NINE NEW GENERIC PRESCRIPTION DRUGS IN 2024, NOW MARKETING SIXTY-ONE GENERIC DRUGS IN CANADA
August 27, 2024
Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada
August 26, 2024
SUNSHINE BIOPHARMA REPORTS 2024 SECOND QUARTER RESULTS, SECOND QTR REVENUES UP 67%, YTD REVENUES UP 61%
August 20, 2024
Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%
August 19, 2024
Sunshine Biopharma Announces Reverse Stock Split
August 6, 2024
Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%
May 21, 2024